IVIg vs placebo
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.88]1 study · 34 participantsLow
Findings
What do systematic reviews say?
4 questions · 4 findings · 2 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%
IVIg vs placebo or no treatment
Overall survival (risk of death) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults 2020 · Cochrane Headline outcomes onlyRR 0.91 [0.23, 3.62]2 studies · 103 participantsVery low
IVIg vs placebo or no treatment
Overall survival (risk of death) ‐ children with myocarditis, 6‐month · children with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults 2020 · Cochrane Headline outcomes onlyRR 0.48 [0.2, 1.15]1 study · 86 participantsVery low
IVIg vs placebo or no treatment
Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults 2020 · Cochrane Headline outcomes onlyRR 1.76 [0.48, 6.4]1 study · 62 participantsVery low